Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
Provided By GlobeNewswire
Last update: May 7, 2025
- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease -
- Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC -
Read more at globenewswire.comNASDAQ:CGTX (6/2/2025, 11:55:53 AM)
0.27
+0.03 (+12.5%)
Find more stocks in the Stock Screener
